Compare HUBC & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUBC | BRTX |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | Israel | United States |
| Employees | 322 | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.3M |
| IPO Year | N/A | 2015 |
| Metric | HUBC | BRTX |
|---|---|---|
| Price | $1.07 | $0.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 348.3K | 290.8K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $0.16 |
| 52 Week High | $7.00 | $1.89 |
| Indicator | HUBC | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 38.26 |
| Support Level | $0.89 | $0.21 |
| Resistance Level | $1.19 | $0.32 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 2.83 | 3.01 |
Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.